NEO - ネオス・ファ―マシュ―ティカルズ （NeoGenomics Inc.） ネオス・ファ―マシュ―ティカルズNEOのチャート
NEOの企業情報
| symbol | NEO |
|---|---|
| 会社名 | Neos Therapeutics Inc （ネオス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Precision Instruments |
| 業種 | ヘルスケア施設_サ―ビス 医療関連（Health Care） |
| 概要 | 事業概要 ネオゲノミクス(NeoGenomics Inc.)はがんに焦点を当てた遺伝子検査ラボのネットワークのオペレーターである。同社は実験室試験事業を運営する。実験室試験事業は病院、病理学者、腫瘍専門医、他の臨床医及び研究者に検査サービスを提供する。同社はフロリダ州マイアーズとタンパ、カリフォルニア州のアリソビエホ、フレズノ、アーバイン、ウエストサクラメント、並びにテキサス州のヒューストンとテネシー州のナッシュビルで実験室を有する。その実験室は細胞遺伝学、蛍光in-situハイブリダイゼーション（FISH）、フローサイトメトリー、免疫組織化学（IHC）、分子検査および病理学相談を含む検査サービスを提供する。製薬サービスと臨床試験グループは、製薬顧客の腫瘍学プログラムを、発見から商品化までサポートするために、テストサービスを提供する。同社は分子スクリーニングのための最適なプラットフォームを推薦し、意味のあるデータを収集するために情報科学を用いてその発見ツールを支援することによって、顧客がバイオマーカー仮説を立てるのに役立つ。 ネオス・ファ―マシュ―ティカルズは米国の医薬品会社。主に薬剤送達技術を利用し、既に商品化されている製薬の改良、開発に従事する。薬剤候補に、注意欠陥多動障害(ADHD)治療薬で、患者の負担が軽い徐放性タイプの経口薬を開発する。また、ADHD治療薬のメチルフェニデ―トとアンフェタミンの両方を取り入れた製薬も開発する。本社はキサス州。 neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig |
| 本社所在地 | 2940 N. Hwy. 360 Grand Prairie TX 75050 USA |
| 代表者氏名 | Douglas M. VanOort Douglas M. VanOort |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 941-923-1949 |
| 設立年月日 | 34639 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 138人 |
| url | www.neostx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/neo |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 26.99500 |
| 終値（lastsale） | 14.34 |
| 時価総額（marketcap） | 1170709082.04 |
| 時価総額 | 時価総額（百万ドル） 1268.162 |
| 売上高 | 売上高（百万ドル） 262.01400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1397.261 |
| 当期純利益 | 当期純利益（百万ドル） -4.77900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 NeoGenomics Inc. revenues increased 10% to $131.2M. Net income applicable to common stockholders totaled $3.7M vs. loss of $5.9M. Revenues reflect Clinical testing segment increase of 7% to $116.5M Pharma Services segment increase of 30% to $14.7M. Net Income reflects Stock-based Compensation in R&D decrease of 18% to $269K (expense). |
NEOのテクニカル分析
NEOのニュース
NeoGenomics, Inc.: NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer 2023/06/05 11:02:00 Finanz Nachrichten
FT. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its …
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer 2023/06/05 11:00:00 Accesswire
FT. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaDaR® assay for the detection of molecular residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Data from a retrospective analysis of the Phase 3 PENELOPE-B study was presented in part at the 2023 ASCO® Annual Meeting on Friday, June 2 nd in Chicago, IL. In collaboration with the trial sponsor, German Breast Group (GBG), the study used NeoGenomics'' RaDaR personalized MRD assay to assess the potential of circulating tumor DNA (ctDNA) analysis to predict future clinical relapse of patients enrolled in the PENELOPE-B trial. " We are delighted that the development of liquid biopsies for the early detection of circulating tumor DNA is moving forward. There is an unmet need for early response evaluation in plenty of clinical situations, and these results support the potential benefits of the clinical utility of individualized assays, such as the RaDaR assay." said Professor Sibylle Loibl, MD, Chief Executive Officer of German Breast Group. "Prognostic and predictive implications of circulating tumor DNA assays still need to be validated on a broader basis.
NeoGenomics, Inc.: NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023/06/01 11:02:00 Finanz Nachrichten
FT MYERS, FL / ACCESSWIRE / June 1, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announ…
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023/06/01 11:00:00 Accesswire
FT MYERS, FL / ACCESSWIRE / June 1, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced the company will be participating in the upcoming Goldman Sachs 44 th Annual Global Healthcare Conference in Dana Point, California. NeoGenomics'' management is scheduled to participate in a fireside chat on Wednesday, June 14 th at 11:20 a.m. Pacific Time/2:20 p.m. Eastern Time. A live and archived audio webcast of the presentation will be available on the "News, Events, and Webcasts" tab via the Investor Relations section of the Company''s website at ir.neogenomics.com . About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company''s Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics, Inc.: NeoGenomics to Showcase the Transformational Impact of RaDaR Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO 2023/05/30 11:02:00 Finanz Nachrichten
FT. MYERS, FL / ACCESSWIRE / May 30, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data supporting its can…
NeoGenomics, Inc.: NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer 2023/06/05 11:02:00 Finanz Nachrichten
FT. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its …
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer 2023/06/05 11:00:00 Accesswire
FT. MYERS, FL / ACCESSWIRE / June 5, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data in support of its RaDaR® assay for the detection of molecular residual disease (MRD) and recurrence in patients with high-risk hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Data from a retrospective analysis of the Phase 3 PENELOPE-B study was presented in part at the 2023 ASCO® Annual Meeting on Friday, June 2 nd in Chicago, IL. In collaboration with the trial sponsor, German Breast Group (GBG), the study used NeoGenomics'' RaDaR personalized MRD assay to assess the potential of circulating tumor DNA (ctDNA) analysis to predict future clinical relapse of patients enrolled in the PENELOPE-B trial. " We are delighted that the development of liquid biopsies for the early detection of circulating tumor DNA is moving forward. There is an unmet need for early response evaluation in plenty of clinical situations, and these results support the potential benefits of the clinical utility of individualized assays, such as the RaDaR assay." said Professor Sibylle Loibl, MD, Chief Executive Officer of German Breast Group. "Prognostic and predictive implications of circulating tumor DNA assays still need to be validated on a broader basis.
NeoGenomics, Inc.: NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023/06/01 11:02:00 Finanz Nachrichten
FT MYERS, FL / ACCESSWIRE / June 1, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announ…
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023/06/01 11:00:00 Accesswire
FT MYERS, FL / ACCESSWIRE / June 1, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced the company will be participating in the upcoming Goldman Sachs 44 th Annual Global Healthcare Conference in Dana Point, California. NeoGenomics'' management is scheduled to participate in a fireside chat on Wednesday, June 14 th at 11:20 a.m. Pacific Time/2:20 p.m. Eastern Time. A live and archived audio webcast of the presentation will be available on the "News, Events, and Webcasts" tab via the Investor Relations section of the Company''s website at ir.neogenomics.com . About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company''s Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics, Inc.: NeoGenomics to Showcase the Transformational Impact of RaDaR Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO 2023/05/30 11:02:00 Finanz Nachrichten
FT. MYERS, FL / ACCESSWIRE / May 30, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, today announced new data supporting its can…
NeoGenomics Inc. (NEO) did well last session? 2023/03/07 16:40:00 US Post News
In Monday’s session, NeoGenomics Inc. (NASDAQ:NEO) marked $17.51 per share, down from $17.99 in the previous session. While NeoGenomics Inc. has underperformed by -2.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NEO fell by -13.83%, with highs and lows ranging from $20.78 to $6.00, whereas […]
Neogenomics: At A Key Inflection Point In Growth Route (NASDAQ:NEO) 2023/03/03 08:55:59 Seeking Alpha
NeoGenomics'' profitability and return on capital are a concern, so FY23 will be the key year to evidence the success of the new strategy. Find out why NEO stock is a Hold.
NeoGenomics upgraded to buy at Benchmark on performance improvement program (NASDAQ:NEO) 2023/02/24 15:57:43 Seeking Alpha
Benchmark has upgraded NeoGenomics (NEO) to buy from hold noting that a management performance improvement program is poised to deliver profitability.